Person:
ATAGÜNDÜZ, IŞIK

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ATAGÜNDÜZ

First Name

IŞIK

Name

Filters

2020 - 20243
Reset filters

Settings

Author: TOPTAŞ, TAYFUR × Start date: 2020 ×

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia
    (CIG MEDIA GROUP, LP, 2020) BOSTAN, HAYRİ; Bostan, Hayri; Toptas, Tayfur; Tanrikulu, Funda Pepedil; Kut, Kevser; Arikan, Fatma; Yilmaz, Fergun; Atagunduz, Isik; Firatli-Tuglular, Tulin
    We assessed the quality of life and symptom burden in patients with chronic-phase chronic myeloid leukemia (CML) receiving first- or second-generation tyrosine kinase inhibitors, to demonstrate whether there are differences between tyrosine kinase inhibitor generations. A total of 121 patients with CML with good performance and low comorbidity scores were enrolled in the study. Similar results were observed between the groups in the quality of life and symptom burden scores, which were examined using CML-specific (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chronic Myeloid Leukemia module, MD Anderson Symptom Inventory for Chronic Myeloid Leukemia) questionnaires. Background: With the advent of tyrosine kinase inhibitors (TKIs), patients with chronic myeloid leukemia (CML) have a life expectancy similar to those of age- and gender-matched healthy populations. Nevertheless, patients receiving TKIs report chronic adverse events such as fatigue, edema, and muscle cramps, which lead to a decrease in their quality of life (QoL). Therefore, the aim of this study was to assess the QoL and symptom burden in patients receiving original imatinib, generic imatinib, dasatinib, and nilotinib. Patients and Methods: A total of 121 patients with CML who received TKIs for at least 3 months were enrolled in the study. The QoL was assessed with the Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and Quality of Life Questionnaire-Chronic Myeloid Leukemia (QLQ-CML24) modules. The symptom burden was assessed with MD Anderson Symptom Inventory for Chronic Myeloid Leukemia (MDASI-CML) and EORTC QLQ-CML24. Results: The median age of the study population was 53 years (range, 28-90 years), and 83 (81.4%) patients had a low-to-medium Sokal risk score. The Eastern Cooperative Oncology Group performance status of most patients were good (< 2; 96%), and comorbidity scores were low (HCT-CI < 3; 90.8%). There was no significant difference between the general health status of patients in terms of EORTC QLQ-C30 and QLQ-CML24. According to the results of the MDASI-CML and QLQ-CML24 modules, the most common symptom was fatigue (58.7%) in all groups, and there were no significant differences between the groups in terms of the effects on the daily life activities of the patients. Conclusion: Patients with CML receiving first- and second-generation TKIs were seen to have a similar QoL and symptom burden. (C) 2020 Elsevier Inc. All rights reserved.
  • Thumbnail Image
    PublicationOpen Access
    The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia
    (2023-01-01) DEMİRTAŞ, DERYA; YANIK, AHMET MERT; ATAGÜNDÜZ, IŞIK; TOPTAŞ, TAYFUR; Candan O., Demirtas D., YANIK A. M., ATAGÜNDÜZ I., TOPTAŞ T.
  • Thumbnail Image
    PublicationOpen Access
    Peripheral T-Cell Lymphoma Coexisting with Autoimmune Hemolytic Anemia: Analysis of Clinical Features
    (2024-01-01) DEMİRTAŞ, DERYA; YANIK, AHMET MERT; YILMAZ, ASU FERGÜN; ATAGÜNDÜZ, IŞIK; TUĞLULAR, AYŞE TÜLİN; TOPTAŞ, TAYFUR; Candan O., Naghizada N., DEMİRTAŞ D., YANIK A. M., Salim S., Menguc M. U., Arikan F., YILMAZ A. F., ATAGÜNDÜZ I., TUĞLULAR A. T., et al.
    Autoimmune hemolytic anemia (AIHA) is characterized by the production of antibodies targeting red blood cells (RBCs) antigens. The diagnosis is based on the presence of a hemolytic anemia with a positive direct antiglobulin test (or Coombs test) and on the absence of any other hereditary or acquired cause of hemolysis, although direct antiglobulin test-negative cases are not quite uncommon (5% of 308 cases of AIHA recently reported by the Gruppo Italiano Malattie EMatologiche dell’Adulto [GIMEMA]) [1, 2]. AIHA can present in primary and secondary forms. Secondary AIHA generally includes factors such as connective tissue diseases, drugs, infections, and lymphomas [3]. Cases of AIHA accompanied by lymphoma are rare and are typically presented in the literature as case reports. Roughly one-fifth of AIHA patients have lymphoma, while 7–10% of lymphoma patients have co-existing AIHA, indicating a clinicopathological link between both diseases [4–6]. In clinical settings, AIHA is commonly associated with indolent B-cell lymphomas, whereas the combination of AIHA with peripheral T-cell lymphoma (PTCL) is rarely observed [7–11]. This study retrospectively analyzes the clinical data, laboratory characteristics, treatment processes, and prognosis of five patients with the coexistence of PTCL and AIHA who were diagnosed within the last 10 years in our center.